GRFSNasdaqPharmaceutical PreparationsAlso trades as GIFLF, GIFOF, GIKLY

Grifols SA

Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 17, 2026

$7.64+0.00 (0.00%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2014 to 2024

38.7%−7.2 pts over 5 years

16.5%−5.7 pts over 5 years

2.2%−10.1 pts over 5 years

Compound annual growth to fiscal 2024

Per year	1 year	3 years	5 years	10 years
Revenue	+9.4%	+13.5%	+7.2%	–
Gross profit	+12.5%	+12.5%	+3.6%	–
Operating income	+52.4%	+26.1%	+1.0%	–
Net income	+270.8%	-6.0%	-24.2%	–
EPS, diluted	+283.3%	-6.3%	-24.0%	–
Free cash flow	–	+24.2%	+21.0%	–

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2015	FY2019	FY2024
Return on equity	–	13.8%	2.8%
Return on assets	–	4.5%	0.7%
Current ratio	–	3.92	2.66
Debt to equity	–	0.76	0.45
Net debt to EBITDA	–	2.05×	1.03×
Interest coverage	4.0×	3.3×	1.7×
Inventory turnover	–	1.3×	1.3×
Capex to revenue	13.3%	6.1%	3.2%
Diluted shares	684M	685M	680M

Return on equity split into margin, efficiency and leverage

Net margin2.2%

Asset turnover0.34×

Equity multiplier3.77×

Return on equity, FY20242.8%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2024	2.2%	0.34×	3.77×	2.8%
FY2023	0.6%	0.31×	3.83×	0.8%
FY2022	3.1%	0.30×	3.62×	3.3%
FY2021	3.8%	0.29×	3.25×	3.6%
FY2020	11.6%	0.35×	3.10×	12.5%
FY2019	12.3%	0.36×	3.10×	13.8%
FY2018	13.3%	0.38×	2.98×	15.2%
FY2017	15.3%	0.41×	2.86×	18.0%